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Purpose: Sirolimus has potent anti-rejection activity as well as the ability to prolong allograft survival and reduce 
nephrotoxicity. This study was designed to evaluate the efficacy and safety of sirolimus in Korean de novo renal 
transplantation. 
Methods: We included 79 patients who received sirolimus at nine Korean transplantation centers in the 
intention-to-treat and valid-for-safety analyses. The study was an open, single treatment arm multicenter trial with 
12 months of patient follow-up. Initially, patients received 2 mg of sirolimus (after 6 mg of loading does) with 
cyclosporine and steroids. Sirolimus was administered for up to 12 months. Antibody induction was not used. 
At 3 months after transplantation, cyclosporine was progressively withdrawn over 4 to 8 weeks while sirolimus 
was adjusted to obtain trough concentrations within 15∼30 ng/ml up to 6 months and concentrations within 
12∼24 ng/ml between 7 and 12 months. 
Results: The proportion of patients who completed the 12-month sirolimus medication per protocol was 74.7% 
(59/79). Cyclosporine withdrawal was possible in 64 recipients (81.0%). Fifteen patients discontinued sirolimus 
before cyclosporine withdrawal, and 5 recipients did so after successful cyclosporine withdrawal. Most common 
causes of sirolimus discontinuation were graft rejection (n=8). Incidence of biopsy-proven acute rejection within 
6 months after transplantation was 15.2%. Patient and graft survival rates at 12 months post transplantation were 
97.5% and 96.2%, respectively. During the study period, three graft losses occurred by patient death. 
Conclusion: Based on this study, cyclosporine and sirolimus induction followed by cyclosporine withdrawal at 
3 months post-transplant is considered to be efficient and safe after primary renal transplantation. (J Korean Surg 
Soc 2010;79:261-266)
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INTRODUCTION
  Cyclosporine (CsA) and tacrolimus are the most widely 
used immunosuppressants for the prevention of acute 
organ rejection. However, due to their activity as calci-
neurin inhibitors (CNIs), CsA and tacrolimus cause 
hypertension, reduction of glomerular filtration rates, and 
chronic allograft nephropathy.(1,2) Given the negative side 
effects associated with CNIs, particularly nephrotoxicity, a 
potent non-CNI immunosuppressant has the potential to 
prolong allograft survival, as well as improve allograft 
function.(3,4) Sirolimus (SRL) has demonstrated potent 
anti-rejection activity and the ability to prolong allograft 
survival.(5) SRL has been reported to act synergistically 
with CsA in the reduction of acute rejection.(6) In a 
previous study, the addition of SRL to CsA and steroids 
significantly reduced the incidence of acute graft rejection 
in renal allograft recipients compared with the control 
regimen of CsA and steroids.(7) Direct SRL versus CsA 
comparison studies demonstrated that SRL has a different 
safety profile. In the SRL arm of the trial, better renal 
function, less hypertension, and fewer tremors were observed; 
however, SRL was associated with greater incidences of 
hyperlipidemia, leukopenia, and thrombocytopenia. Taken 
together, data from phases II and III trials suggest that SRL 
permits a low acute rejection rate when used with CsA and 
that the use of SRL as a base therapy without CsA may 
spare patients from the attendant toxicities of CsA. 
Therefore, in this study, we evaluated the efficacy of SRL- 
based immunosuppression therapy after early CsA with-
drawal, as assessed by the incidence of biopsy-proven acute 
rejection episodes at 6 months, the safety of SRL, and graft 
function and survival over 12 months after transplantation 
in primary renal transplantation recipients in Korea.
METHODS
1) Patients and study protocol
  This phase lllb prospective observational clinical trial was 
an open label, non-comparative, single treatment arm, 
multicenter study which was performed for 12 months. This 
study enrolled end-stage renal failure patients who were 
scheduled to receive a primary renal allograft from a 
deceased donor, a living-unrelated donor, or a living-related 
(excluding 0 antigen mismatch) donor from nine trans-
plantation centers in South Korea between March 2007 
and December 2007. A government-run Korean Network 
for Organ Sharing approved each transplantation surgery.
  The number of patients was calculated by the formula 
under the assumption that binary variable approximately 
had a normal distribution for large patients.(8)
N=(Z/W)2×P×(1−P)
    N = number of patients
Z = 1.9645 (value of the normal standard deviation 
corresponding to the two-sided 95% confidence 
interval)
P=0.17, the anticipated incidence of biopsy-conformed 
acute rejection episode
    W=0.10, the width of confidence interval
  Using the formula, the needed sample size was 55 
patients. Approximately 70 patients were planned to be 
enrolled in the study, considering 20% drop-out rate. We 
recruited 81 patients to ensure a sufficient number of 
patients for analysis.
  SRL treatment was initiated within 48 hours after 
transplantation, and was administered for up to 12 months 
(Fig. 1). CsA treatment was initiated before transplantation 
or within 48 hours after transplantation unless it was 
withheld by local practice for acute tubular necrosis or 
delayed graft function. Corticosteroids therapy was initiated 
within 24 hours before or after transplantation. 
Corticosteroids were administered by local standard 
practice at each study center, and tapered to a minimum 
of 5 mg/day of prednisone orally (or its equivalent) by the 
end of week 13. Withdrawal of corticosteroids was 
prohibited. All patients received SRL, CsA, and 
corticosteroids for 3 months after transplantation. At 3 
months (±4 weeks) following transplantation, CsA was 
progressively withdrawn over 4 to 8 weeks while SRL was 
adjusted to obtain whole blood trough concentrations 
within 15∼30 ng/ml (IMXⓇ, Abbott, Abbott park, IL, 
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Fig. 1. Diagram of study protocol.
USA) up to 6 months and within 12∼24 ng/ml between 
7 and 12 months (Fig. 1). When SRL and CsA were 
co-administered, SRL was administered approximately 4 
hours after the morning dose of CsA; after CsA withdrawal, 
SRL was administered in the morning. This trial was 
approved by the institutional review board of each partici-
pating transplantation center, and it was monitored internally 
and externally.
2) Efficacy assessments
  The primary efficacy endpoint was the incidence of 
biopsy-proven acute rejection episode at 6 months after 
transplantation. Renal biopsy was taken when acute 
rejection was suspected. For patient management, the inter-
pretation of the pathologist at each site was used to define 
acute rejection according to the Banff 97 criteria for 
classification. Secondary efficacy endpoints included graft 
function at 6 and 12 months after transplantation (as deter-
mined by serum creatinine and e-GFR by Nankivell 
equation(9)) and patients and graft survival at 6 and 12 
months after transplantation. The analysis of the data was 
based on an intention-to-treat (ITT) analysis. The summary 
of statistical analysis reported the number of patients with 
suspected and actual acute rejection events and the number 
of events per patient. This summary presented overall and 
monthly figures and figures for other appropriate time 
intervals. The percentage of patients with acute rejection 
over 6 months was reported along with corresponding 95% 
2-sided confidence interval.
3) Safety assessment
  Patients who received at least one dose of SRL were 
included in this analysis. All of the observed adverse events 
(AEs) were properly categorized, and then occurrence rates 
and confidence intervals were calculated. AEs were classified 
by using the Medical Dictionary for Regulatory Activities 
(MedDRA) 10.1.
RESULTS
1) Patient characteristics
  A total of 81 patients were enrolled, but 2 patients were 
immediately excluded before transplantation due to cancel-
lation of surgery (n=1) and withdrawal of consent before 
surgery (n=1). The remaining 79 patients who received 
kidney from living-related (n=63), living-unrelated (n=9) or 
deceased (n=7) donors composed the ITT analysis pop-
ulation. Of 79 patients, 59 (74.7%) completed medication 
for 12 months per protocol. Fifteen patients discontinued 
SRL before CsA withdrawal, and 5 recipients stopped the 
treatment after successful CsA withdrawal. Most common 
causes of SRL discontinuation were graft rejection (n=8) 
and protocol violation (n=3). Our patient demographics are 
presented in Table 1. Among them, 47 (59.5%) were 
264 J Korean Surg Soc. Vol. 79, No. 4
Table 1. Demographics of study patients (n=79)
Characteristics No. of patients (%)
  Sex
    Female 47 (59.49)
    Male 32 (40.51)
  Age (year)
    Mean±SD 40.16±12.69
    Median 41.00
    Min, Max 14.00, 65.00
    10≤, ＜30 22 (27.85)
    30≤, ＜50 33 (41.77)
    50≤, ＜70 24 (30.38)
  Height (cm)
    Mean±SD 164.15±9.15
    Median 165.00
    Min, Max 143.50, 184.00
  Weight (kg)
    Mean±SD 61.63±10.25
    Median 60.80
    Min, Max 38.00, 89.60
  CMV* status
    Negative 3 (3.80)
    Positive 76 (96.20)
  Primary etiology
    Hypertension 33 (41.77)
    Glomerulonephritis 13 (16.46)
    Diabetes mellitus 10 (12.66)
    Polycystic disease-kidney 3 (3.80)
    Interstitial nephritis/pyelonephritis 1 (1.27)
    Other/unknown 19 (24.05)
  No. of HLA† mismatches
    Mean±SD 2.29±0.88
    Median 3.00
    Min, Max 0.00, 4.00
    0 3 (3.80)
    1 12 (15.19)
    2 24 (30.38)
    3 39 (49.37)
    4 1 (1.27)
  Panel of reactive antibodies (%PRA)
    Mean±SD 2.14±7.96
    Median 0.00
    Min, max 0.00, 45.00
  Chest X-ray 
    Normal 67 (84.81)
    Abnormal-not clinically significant 12 (15.19)
    Abnormal-clinically significant 0 (0.00)
  ECG‡
    Normal 42 (53.16)
    Abnormal-not clinically significant 37 (46.84)
    Abnormal-clinically significant 0 (0.00)
Table 1. Continued
Characteristics No. of patients (%)
  Physical examination
    Normal 78 (98.73)
    Abnormal 1 (1.27)
  Prior non-pharmacologic treatment procedure
    Yes 75 (94.94)
    No 4 (5.06)
*CMV = cytomegalovirus; †HLA = human leucocytes antigen; ‡ECG
= electrocardiogram.
female, and 32 (40.5%) were male. All patients were Korean. 
CsA withdrawal was initiated a mean of 96.1±14.2 days 
after transplantation, and 33.0±15.1 days were required to 
complete CsA withdrawal.
2) Dose and trough levels of immunosuppressive 
drugs
  The mean daily dose and trough concentrations of SRL 
and CsA were summarized in Fig. 2. One week after CsA 
withdrawal, the mean SRL trough level was 15.8±5.2 ng/ml. 
At 4 weeks after CsA withdrawal, it was 16.2±4.2 ng/ml.
3) Efficacy evaluations
  The incidence of biopsy-confirmed acute rejection 
episodes at 6 and 12 months after transplantation was 15.2% 
and 19.0% respectively 79 recipients. No subject had more 
than 2 acute rejection episodes. Eleven episodes were 
reported before CsA withdrawal and 1 episode after CsA 
withdrawal. The mean e-GFR at 6 and 12 months after 
transplantation was 67.4±15.3 ml/min and 71.9±18.8 ml/ 
min respectively in the 79 ITT set. The mean serum 
creatinine level at 6 and 12 months after transplantation 
was 1.3±0.4 mg/dl and 1.3±0.4 mg/dl respectively in the 
79 ITT set. There were no graft losses except ones due to 
patient death, with no causal relationship between graft 
loss and the study drug as determined by the investigator. 
The patient and graft survival rate at 12 months after 
transplantation was 97.5% and 96.2% respectively.
4) Safety evaluation
  All patients reported at least one episode of AE. Among 
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Fig. 2. Dose and trough level of sirolimus (A) and cyclosporine (B) after transplantation by month.
Table 2. Changes in hematologic and lipid profiles
Time
No. of
patients
Hemoglobin
(g/dl)
Hematocrit
(%)
Cholesterol
(mg/dl)
Triglycerides
(mg/dl)
HDL-cholesterol
(mg/dl)
  Screening 79 10.45±1.73 31.20±5.37 160.09±35.91 122.91±67.88 44.71±14.06
  Month 1 71 11.73±1.31 34.94±3.95 No check No check No check
  Month 6 62 12.49±1.59 38.02±5.10 235.55±46.94  197.85±155.32  68.52±19.68
  Month 12 59 12.78±1.78 39.36±5.57 224.63±43.41 189.63±99.73 63.59±19.3
them, 78.5% patients reported 143 episodes of infection. 
The incidence of AEs related to the study drug was 91.1%, 
and infections related to the study drug were 46.8%. By 
system organ class using MedDRA 10.1, gastrointestinal 
disorders were most frequently reported in 66 patients 
(83.5%). The most frequently reported AE other than 
infection, was constipation (38.0%), serum cholesterol 
elevation (36.7%), and diarrhea (27.9%). Simple upper 
respiratory tract infection was the most common type of 
infection. SAEs were reported in 39 patients (49.4%). The 
most frequently reported SAEs were elevated serum creati-
nine concentration (12.7%), lymphocele (7.6%), herpes 
zoster infection (7.6%), and pulmonary infection (6.3%). 
Seven SAEs (5 lymphoceles, 1 ventral hernia, and 1 wound 
seroma) with wound healing were reported, and the investi-
gators concluded that only 5 SAEs were related to SRL.
  Hematology and blood chemistry, lipid profile of 
patients are presented and summarized in Table 2. There 
was a change during study period. However, most hematologic 
test results were within normal ranges, and no clinical 
toxicity was observed. The cholesterol level was 160.09± 
35.91 mg/dl at screening and 224.63±43.41 mg/dl at 12 
months after transplantation. The mean triglyceride level 
was 122.91±67.88 mg/dl at screening stage, 189.63±99.73 
mg/dl at 12 months after transplantation.
DISCUSSION
  This is prospective observational and first pilot study 
about the efficacy and safety of SRL in Korean renal trans-
plantation recipients. However, the study population was 
relatively smaller than previous study performed in other 
countries. This study is originally planned and performed 
as a pilot study before commercial use of SRL. In Korea, 
SRL is not supported by the National Medical Insurance 
Program. So, study population cannot use SRL as a main 
immunosuppressant freely after study period. This point is 
one of the limitations in the SRL use and expanding study 
population.
  The use of SRL has been directly compared to that of 
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CsA in two phase II trials for the prevention of acute 
rejection in renal allograft recipients. In these studies, SRL 
was shown to have efficacy similar to CsA in preventing 
acute graft rejection, although the observed acute rejection 
rates were higher than those obtained with the SRL-CsA 
combination.(10,11) The incidence of acute rejection con-
firmed by biopsy within 6 and 12 months in this study 
was 15.2% (12/79) and 19.0% (15/79) respectively. This 
result is similar to 17.2% (37/215) and 20.0% (43/215), 
in the same order, found in the previous study in other 
countries.(4) Most episodes of acute rejection occurred 
before CsA withdrawal. Only 3 episodes of acute rejection 
occurred after CsA withdrawal. We can confirm that our 
efficacy and safety profiles are similar to those of the 
previous study.
  During the study period, 3 patients died with no causal 
relationship to the study drug. A 49-year-old male died 
from asphyxia one month after. A 50-year-old male was 
found dead in his house 7 months after study medication 
began. There were no AEs reported in this patient. Cause 
of death was presumed as a myocardial infarction according 
to his medical record. A 58-year-old female who started 
the study medication on November 6, 2007, stopped on 
November 26, 2007 due to thrombocytopenia and pneu-
monia. She died from myocardial infarction on January 16, 
2008. While the investigator concluded that her throm-
bocytopenia and pneumonia was related to SRL, but the 
myocardial infarction was not related to SRL.
  Based on this study, CsA and SRL induction followed 
by CsA withdrawal at 3 months post-transplant is considered 
to be efficient and safe after primary renal transplantation. 
SRL maintenance regimen has been shown to be an effec-
tive treatment for the prevention of renal acute rejection 
episodes in primary renal allograft recipients.
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